Charles Schwab Investment Management Inc Anavex Life Sciences Corp. Transaction History
Charles Schwab Investment Management Inc
- $519 Billion
- Q2 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 651,084 shares of AVXL stock, worth $3.7 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
651,084
Previous 630,067
3.34%
Holding current value
$3.7 Million
Previous $3.21 Million
14.34%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding AVXL
# of Institutions
152Shares Held
26.5MCall Options Held
674KPut Options Held
811K-
Black Rock Inc. New York, NY6.39MShares$36.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.55MShares$25.8 Million0.0% of portfolio
-
State Street Corp Boston, MA3.74MShares$21.2 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.83MShares$10.4 Million0.0% of portfolio
-
Two Sigma Investments, LP New York, NY1.01MShares$5.75 Million0.01% of portfolio
About ANAVEX LIFE SCIENCES CORP.
- Ticker AVXL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,942,800
- Market Cap $443M
- Description
- Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...